This Web site is developed and maintained under the editorial direction of diagnosticimaging.com, the Web site of Diagnostic Imaging magazine and its related publications.
It is the goal of this Web site to be the Web’s most comprehensive and up-to-date source of information on radiofrequency ablation and other energy-based tumor ablation therapies.
Material for this site is developed by physicians and medical journalists. Material also comes from the pages of Diagnostic Imaging magazine and its related publications, from Oncology News International magazine, and from reports published at www.diagnosticimaging.com.
Editorial director:
John C. Hayes, john.hayes@cmpmedica.com
Contributing editors:
Sarah Jersild, sjersild@gmail.com
H.A. Abella, habella@cmp.com
Copy editors:
Kathleen Lawrence
Frances Taylor
Web Master:
DIWebMaster@cmp.comEditorial questions: Inquiries should be directed to the Editor, Diagnostic Imaging, 600 Harrison St., San Francisco, CA 94107, 415/947-6472, john.hayes@cmpmedica.com.
DISCLOSURE: The editorial material on this Web site is published solely by CMP Healthcare Media Group LLC, the publisher of Diagnostic Imaging. CMP Media LLC does not endorse the appropriateness of or are responsible for any actions taken by third parties on the basis of material available at this Web site.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
